anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Perioperative administration of TXA reduces bleeding risk in surgical patients. However, large clinical trials have excluded patients with advanced kidney disease, so the benefits remain uncertain in this population, and there is potential for harm. The benefit of desmopressin, which is purported to more directly address the defect of primary hemostasis believed important in severe kidney disease more directly than TXA, has not been examined in adequate randomized control trials (RCTs). Both medications are generic and have been available for many years. To convincingly test these medications in patients with severe kidney disease, large, global trials are required. This pilot-phase trial will 1) inform the feasibility and design of a large international trial to evaluate the efficacy and safety of TXA and desmopressin in patients with severe kidney disease undergoing noncardiac surgery, 2) provide preliminary data regarding the efficacy and safety of TXA and desmopressin in people with advanced kidney disease having noncardiac surgery, and 3) provide pharmacokinetic data to inform dose selection.
The invention discloses vanilla scented tea concentrated juice and a preparation method thereof. The concentrated juice is prepared from, by weight of dry matter, 55-65% of lemongrass, 15-20% of stevia rebaudianum, 10-15% of mint and 5-10% of a mixture of two kinds of flowers. The components are solid raw materials. The total weight percentage of the components is 100%. The mixture of the two kinds of flowers is formed by mixing jasmine flowers and calendula according to the mass ratio of 3:1. The vanilla scented tea concentrated juice is prepared through the steps of preprocessing, extraction, filtering, vacuum concentration, drying and the like. The prepared vanilla scented tea concentrated juice has the health-care effects of regulating qi, soothing the liver, promoting appetite, beautifying faces, being resistant to senescence, moisturizing skin and the like, and has a relieving function on stress relieving and nerve calming. Meanwhile, the flavone content of the concentrated juice is as high as 211.33 mg/g, the polysaccharide content is as high as 20.67 mg/g, and the concentrated juice has the functions of reducing blood fat, being resistant to viruses and tumor, inhibiting bacteria and protecting the liver and being resistant to senescence and radiation, and can enhance immunity of human bodies.
When risperidone oral solution is co-administered with enzyme inducers (e.g., carbamazepine), the dose of risperidone oral solution should be increased up to double the patient's usual dose. It may be necessary to decrease the risperidone oral solution dose when enzyme inducers such as carbamazepine are discontinued [see Drug Interactions (7.1)]. Similar effect may be expected with co-administration of risperidone oral solution with other enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital).  
  
When fluoxetine or paroxetine is co-administered with risperidone oral solution, the dose of risperidone oral solution should be reduced. The risperidone oral solution dose should not exceed 8 mg per day in adults when co-administered with these drugs. When initiating therapy, risperidone oral solution should be titrated slowly. It may be necessary to increase the risperidone oral solution dose when enzyme inhibitors such as fluoxetine or paroxetine are discontinued [see Drug Interactions (7.1)].
BACKGROUND: Pulmonary inhaler therapy is a core treatment modality for >600 million individuals affected by obstructive airways disease globally. Poor inhaler technique is associated with reduced disease control and increased health care utilization; however, many patients rely on the internet as a technical resource. This study assesses the content and quality of online resources describing inhaler techniques.
METHODS: A Google search was conducted in April 2023 capturing the top 5 search results for 12 common inhaler devices. Websites were compared to product monographs for preparation/first use, inhalational technique, and post-usage/device care. They were also assessed using accepted quality metrics (GQS, DISCERN, JAMA Benchmark scores) and clinically relevant aspects based on the literature and consensus statements.
RESULTS: Websites regularly excluded critical steps important for proper inhaler technique. They performed best on information related directly to inhalation technique (average median score 78%), whereas steps related to preparation/first use (58%) or post-usage/device care (50%) were less frequently addressed. Median GQS, DISCERN, and JAMA Benchmark scores were 3 [IQR 3-4], 3 [IQR 2-4], and 1 [IQR 1-3], respectively. Clinically relevant factors were only addressed in about one-fifth of websites with no websites addressing smoking cessation, environmental considerations, or risk factors for poor technique.
CONCLUSIONS: This study highlights gaps in online resources describing inhaler technique, particularly related to preparation/first use and post-usage/device care steps. Clinically relevant factors were rarely addressed across websites. Improvements in these areas could lead to enhanced inhaler technique and clinical outcomes.
OBJECTIVES: Irritability is a foundational clinical reasoning concept in rehabilitation to evaluate reactivity of the examination and treatment. While originally theorized to reflect tissue damage, a large body of evidence supports pain is a biopsychosocial experience impacted by pain sensitivity and psychological factors. Therefore, the purpose of this study was to examine biopsychosocial contributors to irritability.
METHODS: 40 patients with shoulder (n = 20) and low back (n = 20) pain underwent Quantitative Sensory Testing (QST) (Pressure Pain Threshold, Heat Pain Threshold, Conditioned Pain Modulation, Temporal Summation), completed pain-related psychological questionnaires, an Exercise-Induced Hypoalgesia protocol, and standardized irritability assessment based on Clinical Practice Guidelines. Participants were then categorized as irritable or not irritable based on Maitland's criteria and by irritability level based on Clinical Practice Guidelines. An independent samples t-test examined for differences in QST and psychological factors by irritability category. A MANOVA examined for differences in QST and psychological factors by irritability level (high, moderate, low).
RESULTS: Significantly lower heat and pressure pain thresholds at multiple locations (p < 0.05), as well as less efficient conditioned pain modulation (p = 0.02), were demonstrated in individuals categorized as irritable. Heat and pressure pain thresholds were also significantly lower in patients with high irritability compared to other levels. Significantly higher depression and anger, as well as lower self-efficacy, were reported in individuals with an irritable presentation.
DISCUSSION/CONCLUSION: Biopsychosocial factors, including widespread hyperalgesia and elevated psychological factors, may contribute to an irritable presentation.
The present invention discloses compound oral liquid called Niuduning for treating calf diseases and a preparation method. The oral liquid comprises a preventing agent and a therapeutical agent, and is mainly used for preventing and treating diarrhea of newly born calves younger than the age of 3 months. The oral liquid comprises the main components of sodium selenite, acetylsalicylic acid, paracetamol, aminophenazone, sufisomezole, sulfanilamide-5-oxymethylpyrimidine, trimethoprim and maquindox. The preparation method comprises: various components are orderly added into boiled water according to quantities, the temperature above 90 DEG C is maintained, the components are stirred and bottled, and bottles are sealed. The present invention is used for preventing diarrhea diseases of calves, and an effective rate reaches 89.4%. The present invention is used for treating diarrhea diseases of calves, and a cure rate reaches 86.58%.
Trametinib will be administered in 28-day cycles, given once daily or adjusted as per clinical judgment of the treating physician, with a maximum dosage of 2mg daily. Patients will be followed for 4 years after receiving treatment for two years. Patients may continue on the same treatment beyond two years if they and their treating physicians agree to do so in the best interest of the patient.
Participants will be given 6 placebo capsules twice a week for 24 weeks. Placebo capsules are identical in appearance and smell as FMT capsules but contain milk powder.
CKD subjects will be randomized to exercise training (to squeeze a tennis ball repeatedly for at least 30 min/day) or no exercise training for 28 days. Procedures in baseline visit will be repeated followed by cross over to alternate group for 28 days followed by repeat of baseline procedures.
The invention provides a method for preparing eucommia medicine-bath liquid by using ethanol at normal temperature. The eucommia refers to branches, leaves, barks, male flowers and key fruits of eucommia trees. The method comprises the following steps: rolling, mashing and crushing eucommia raw material at normal temperature, and then leaching and clarifying the material by using an ethanol solution so as to prepare the ethanol-eucommia medicine bath liquid. The ethanol-eucommia medicine bath liquid can be used independently or used together with an existing medicine-bath product. Like medicinal liquor, the ethanol-eucommia medicine bath liquid can be stored for a long time with stable medicine property. The water temperature of a medicine bath is generally from 36 DEG C to 40 DEG C, the ethanol-eucommia medicine bath liquid is added within the temperature range, and the active ingredients of the eucommia can fully act on a human body and are absorbed by the human body. The ethanol-eucommia medicine bath liquid is simple in processing method, low in investment and applicable to processing and production of all eucommia planting industrial parks. The ethanol eucommia medicine-bath liquid provides a new industry and new product for the field of processing of the eucommia industry and the medicine bath health care products.
Smoking is a myocardial infarction (MI) risk factor among people with HIV (PWH). Questions persist regarding the role of smoking behaviors and measurements (e.g., intensity, duration) on MI risk. We used Cox proportional hazards regression to compare the association of smoking parameterization with incidents of type 1 and type 2 MI and whether smoking intensity or duration improves MI risk prediction among PWH. Among 11,637 PWH, 37% reported currently smoking, and there were 346 MIs. Current smoking was associated with type 1 (84% increased risk) but not type 2 MI in adjusted analyses. The type 1 MI model with pack years had the best goodness of fit compared with other smoking parameterizations. Ever or never parameterization and smoking diagnosis data had significantly poorer model fit. These results highlight the importance of differentiating MI types and performing patient-based smoking assessments to improve HIV care and research rather than relying on smoking status from diagnoses.
Alisertib 30 mg enteric-coated tablets (ECT), orally, twice a day (BID) for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 16 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
The risk for comorbid major depressive disorder and obesity is increased in adolescents and adults with attention-deficit/ hyperactivity disorder (ADHD), and adolescent ADHD predicts adults major depressive disorder and obesity. Nonpharmacological interventions to prevent these comorbidities are urgently needed. Bright light therapy (BLT) improves day-night rhythm and is an established therapy for major depression in adolescents and adults. Exercise prevents and reduces obesity in adolescents and adults and also improves depressive symptoms. Interestingly, a reinforcement-based intervention using a mobile health app (m-Health) resulted in improved effects on weightloss in obesity. The aim of the current pilot randomized-controlled phase-IIa study is to establish feasibility and effect sizes of two kinds of interventions, BLT and exercise, in combination with m-Health based monitoring and reinforcement in adolescents and young adults aged 14 to 45 years old with ADHD, targeting the prevention of depressive symptoms and obesity. In addition, immediate and long-term treatment effects on ADHD specific psychopathology, health related quality of life, fitness and body related measures, neurocognitive functions and chronotype are explored. Furthermore, saliva samples are taken in a subgroup of adult patients to explore the effects of BLT and exercise on concentrations of hormones. This subgroup of adult patients will also participate in an additional neuroimaging study of the reward system in order to explore intervention effects on striatal reward reactivity.
In the present investigation the investigators expect to know the effect of the administration of losartan / amlodipine in fixed combination versus losartan on hemodynamic parameters and arterial stiffness in patients with arterial hypertension grade 1 and 2. For this purpose the investigators will conduct a double-blind randomized trial, each group will be compose by 14 male and female patients, 40-65 years old, with hypertension, neither with diabetes nor being under triple pharmacological therapy. Randomization will determine who will receive the intervention during an 8- week trial (losartan/amlodipine in fixed combination capsule, 100mg/5mg 1 time daily or losartan capsule 100mg 1 time daily). The clinical findings and laboratory tests include a metabolic profile and biosafety, which will be at baseline and by the 8th week . Body weight, body fat, body mass index (BMI) and blood pressure will be determined during the initial and final visit, in addition to hemodynamics parameters of arterial stiffness like cardiac output, central aortic pressure (CAP), pulse wave velocity (PWV) and peripheral vascular resistance (PVR) by an oscillometric monitoring system via Mobil-O -Graph® 24. Adverse events and adherence to treatment will be documented. Statistical analysis: Mann-Whitney U Test and Wilcoxon exact test. It is considered with significance at p\<0.05.
The invention relates to a skin whitening cream. The skin whitening cream comprises the following components in parts by weight: 0.05-0.08 part of melatonin, 3-5 parts of plant extract, 0.3-0.6 part of levorotatory VC, 10-25 parts of plant oil, 0.5-2.5 parts of arbutin, 2-6 parts of emulsifier, 4-8 parts of humectants, 0.2-0.4 part of essence, 0.1-0.3 part of Paraben, and 65-85 parts of water. The plant oil is olive oil or castor oil, and the humectant is one or more of glycerol, hyaluronic acid and tartaric acid. The main component of the skin whitening cream provided by the invention is a skin whitening cream extract with a skin whitening effect. The skin whitening cream provided by the invention has the advantages that the skin whitening cream has a favorable skin whitening effect, and is temperate and inirritative. In addition, the skin whitening cream is specially added with the melatonin. Through the cutaneous absorption, the melanin of the skin can be reduced, and the composition of the melanin of the human body can be blocked, so that the skin whitening cream can fundamentally whiten the skin, and also delay the skin aging. The plant oil replaces the chemical grease, so that the skin whitening cream is rapid to absorb, natural and safe.
Reactive polymers can be conjugated, directly or by means of linkers and/or others polymers to chelating agents comprising at least one phosphorous atom in the form of a phosphine or phosphine oxide (or precursors thereof) to form conjugates useful in diagnostic and therapeutic applications. In particular this invention provides conjugates comprising a hydrophilic polymer bound, directly or by means of other moieties, to at least one chelating group able to chelate metal radioisotopes comprising at least one phosphine or one phosphine oxide phosphorous. Such chelating groups can be conjugated to the hydrophilic polymer directly or via one or more linkers and/or one or more additional polymers. The use of additional polymers can provide increased loading of chelating agent. The linkers are preferably selected among alkyl groups or aromatic groups or cleavable peptides or other biodegradable sequences. Additionally, one or more targeting molecules can be linked to the hydrophilic polymer directly or by means of linkers and/or others polymers. Due to their polymeric structure, the conjugates according to the invention have enhanced specificity toward certain tissues, such as tumors, inflamed tissued and the liver. The specificity can be further increased by the additional provision of targeting moieties such as antibodies or sugars. These conjugates can be formulated for remaining in the blood circulation for a period for time suitable for diagnostic and therapeutic applications. Moreover they possess thermodynamic and kinetic stability, keeping the metal chelate intact under physiological conditions. The invention also provides a very simple and efficient method for the labelling of radiopharmaceuticals, which avoids the use of any additional reducing agent. Accordingly, metal ions like technetium or rhenium can be added as pertechnetate or pherrhenate to chelating agents comprising polymer and a phosphine and surprisingly it has been found that such chelating agents can act as reducing agents of the metal and the use of an additional reducing agent is not necessary. This allows the preparation of simple kits comprising a component (a) comprising the polymeric chelating agent and a component (b) comprising the metal ion in its highest oxidation state. These two components can be kept separately and combined together just before use to yield the metal complex without the need of further reducing step and purification.
PROBLEM TO BE SOLVED: To obtain an external preparation having excellent promoting action on blood circulation by making the external preparation include a specific adenosine as an active ingredient. SOLUTION: This external preparation comprises adenosine, adenosine 5'-phosphoric acid and/or an adenosine 5'-phosphate as an active ingredient. The amount of the active ingredient in the external preparation mixed is, in the case of the external preparation being a hair tonic, preferably 0.01-20.0 wt.% in the total amount of the hair tonic. Consequently, the external preparation capable of promoting blood circulation in the vicinity of skin (in the skin or in the muscle to be reached by percutaneous absorption) and contributing to beauty and health is obtained. The external preparation can be administered by dermal administration by direct application or spray to skin. The daily dose is 0.01-100.0 mg per kg in the case of human. Preferably, the external preparation is administered once or dividedly twice to four times daily.
Fetal primary hydrothorax is a rare congenital anomaly with an estimated incidence of 1:10,000-15,000 pregnancies, with an unpredictable clinical course, ranging from spontaneous resolution to fetal death. A case of unilateral fetal pleural effusion was diagnosed at 35th week of gestation during a routine ultrasonographic fetal assessment in an uncomplicated pregnancy. A large echogenic collection of fluid was revealed in the right pleural cavity, together with atelectasis of the right lung, as well as displacement of heart and mediastinal structures to the left side of thorax. The patient was also diagnosed with polyhydramnios and there was a disproportion of heart ventricles volume. No other fetal structural abnormalities were detected and there were no symptoms of edema. Fetal biometrics was consistent with the gestational age. In echocardiography, fetal heart was structurally and functionally normal. Screening tests for congenital infections of the fetus were negative. Autoimmune fetal hydrops was excluded after laboratory tests. There was no parents' consent for the analysis of the karyotype. The patient presented clinical symptoms and was diagnosed with Herpes simplex virus infection and was treated with oral acyclovir. Serial fetal ultrasound exams showed gradual decrease in pleural fluid volume up to complete resolution in 38th week of pregnancy. Pregnancy was ended in the 38th week of gestation with a cesarean delivery of a healthy neonate. It is yet to be determined if there is a direct association between Herpes simplex virus infection in pregnancy and the risk of fetal pleural effusion. The incidence of fetal pleural effusion is low and the neonatal outcome difficult to be predicted. The optimum management of fetal pleural effusion should be subject to further studies to determine the best clinical practice.
Compositions, kits and methods for boosting, or for priming and boosting, high titer broadly neutralizing cross-clade antibody responses focused on single HIV-1 neutralizing epitopes are disclosed. gp120 DNA plasmids comprising HIV env genes are used to prime the antibody response. Primed subjects are immunized with recombinant fusion proteins that comprise a 'carrier' protein fusion partner, preferably a truncated form of the MuLV gp70 Env protein, and a desired HIV neutralizing epitopes. Preferred epitopes are epitopes of V3 from one or more HIV clades. Immune sera from such immunized subjects neutralized primary isolates from virus strains heterologous to those from which the immunogens were constructed. Neutralizing activity was primarily due to V3-specific antibodies and cross-clade neutralizing Abs were present. This approach results in more potent and broader neutralizing antibody levels, a result of 'immunofocusing' the humoral immune response on neutralizing epitopes such as V3.
PURPOSE:To obtain the titled drug preparation, easily at a low cost, by adding a reducing substance such as ascorbic acid, and a hygroscopic saccharide such as maltitol to bifidus bacteria, controlling the water-content of the mixture to a specific level, and sealing and packaging the mixture with a specific film. CONSTITUTION:1pt.wt. of bifidus bacteria (dry basis) are mixed with 1-10pts.wt. of a reducing substance such as ascorbic acid, erythorbic acid, or their sodium salt, etc. and 1-10pts.wt. of a hygroscopic polysaccharide such as maltitol, sorbitol, a low-molecular dextrin, etc., and the mixture is sealed and packed in a state controlled to a water-content of <=3wt%, with a film shielding the outer atmosphere and light (e.g. laminate of aluminum foil and synthetic resin film) to obtain a bifidus bacteria preparation preservable for a long period. The present preparation enables to take active bifidus bacteria at any time and place, and consequently contributes largely to the health of people.